MedPath

Study of effects of testosterone replacement therapy in hypogonadal men with type 2 diabetes mellitus

Phase 4
Conditions
Health Condition 1: E116- Type 2 diabetes mellitus with other specified complications
Registration Number
CTRI/2019/09/021175
Lead Sponsor
Dr Ronak Gandhi
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Open to Recruitment
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

Patient age between 30 -60 years with symptoms of hypogonadism using the Aging Male Symptom Scale (AMS) score >=27 or the presence of following three sexual symptoms

Decreased sexual interest

Absent or rare morning erections and

Erectile dysfunction

Patientâ??s morning (7am-9am) serum total testosterone level <12 nmol/

Exclusion Criteria

Following patients will be excluded

Patient suffering from severe debilitating disease

History of prostate or breast cancer

Elevated hematocrit (PCV >48%)

Elevated prostate-specific antigen (PSA >4.0 ng/ml; PSA >3 with a high risk)

PSA increase >1.4ng/ml within any 12 month period

Palpable prostate nodule and induration on digital rectal examination (DRE)

Severe obstructive sleep apnea (OSA)

Severe lower urinary tract symptoms (LUTS) (International Prostate Symptom Score [IPSS] >19 )

Previously treated hypogonadism

Acute coronary event in last 6 months

Chronic obstructive lung disease

Recent use of PDE-5 inhibitors (within last 6 months)

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath